TRENDS
Novo Nordisk launches blockbuster weight loss drug Wegovy in India
The drug will follow a four-week cycle for dosage, starting with the smallest dose of 0.25 mg per week for four weeks, followed by a gradual increase in dosage.
BUSINESS
Indira IVF acquires Ahmedabad-based Banker IVF to expand fertility care services
The collaboration will increase Indira IVF's presence in Gujarat, adding to its existing centers in Ahmedabad, Vadodara, Rajkot, Mehsana, and other key locations, the company said.
BUSINESS
Biocon’s Rs 4,500 crore QIP to help retire debt, fuel new launches, says CEO Sidharth Mittal
Biocon’s debt profile has been under investor scrutiny after a strategic acquisition of Viatris Inc's biosimilars business for roughly $3.3 billion in 2022. This deal, while transformative for Biocon Biologics, had significantly increased the company's leverage.
BUSINESS
What does Gilead’s twice-a-year shot means for fight against HIV? When will India get Yeztugo?
The US FDA on June 18 gave its nod to Yeztugo, which can prove to be turning point in the battle against HIV but its high price and access remains a concern
BUSINESS
How a Mumbai startup stepped up during Covid to disrupt the global biopharma supply chain
Founded in 2017 by industry veterans Ankush Kapoor and Sachin Joshi, PharmNXT pivoted from being a distributor of European bioprocessing technologies to becoming a full-fledged manufacturer—building India’s first domestic supply chain for single-use biopharma systems.
BUSINESS
Abbott to distribute MSD's diabetes drug and its combinations in India
The drug patents expired in India in July 2022, which has triggered a wave of generic launches and steep price corrections across the market.
BUSINESS
Indian pharma companies sit on record cash pile, set sights on acquisitions
In FY25 alone, the cash pile increased by over Rs 10,200 crore, underscoring a decisive shift in the capital allocation priorities of India’s drugmakers
BUSINESS
Quadria Group launches $300 million HealthQuad Fund III to build India’s largest healthcare investment platform
HealthQuad Fund III will focus on early to late-stage investments across India’s healthcare value chain, targeting tech-enabled models in diagnostics, chronic care, and digital health.
BUSINESS
Indian drugmakers gearing up to target global weight-loss market as semaglutide patents begin to expire in 2026
Industry executives say the opportunity is “massive,” with demand expected to surge as prices fall.
BUSINESS
Serum Institute, DNDi in pact to develop affordable dengue antibody therapy for lower-income nations
The collaboration will focus on advancing the potential drug candidate—formerly known as VIS513—through Phase III clinical trials in India, Brazil and other dengue-endemic countries.
BUSINESS
Even Healthcare bets big on hospital expansion, targets 25 facilities in 36 months
The hospitals will not offer tertiary services such as oncology or cardiac care, allowing for a leaner capex model with an average investment of $3.5 million per hospital, Even Healthcare co-founder and COO Matilde Giglio tells Moneycontrol, as the company pivots from digital-first care to full-stack healthcare delivery
BUSINESS
OneSource gears up for launch of generic anti-diabetes, obesity drugs, looks to double revenue in 3 years
The patent for semaglutide, the active ingredient in blockbuster Ozempic and Wegovy, expires in more than 100 countries, including India, in 2026. The generic semaglutide launch will redefine OneSource's growth trajectory, CEO Neeraj Sharma tells Moneycontrol
BUSINESS
Renalyx unveils indigenously built low cost dialysis machine
The dialysis machine called RENALYX – RxT 21 with a starting price of ₹6.70 lakh, with an aim to reduce the total cost of ownership by 40% compared to imported alternatives.
BUSINESS
Eli Lilly 'encouraged' by response to weight-loss drug Mounjaro in India, maps expansion
Since its launch in late March, Mounjaro sales have trebled. Winselow Tucker, president and general manager of Lilly in India, says the drugmaker is tying up with healthcare players to spread awareness about the dual epidemic of obesity and diabetes
BUSINESS
Biocon, Wockhardt, Eris to double insulin output, as global drugmakers scale back to focus on GLP-1, new generation insulins
Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in emerging markets.
BUSINESS
HealthKois launches $300-million fund to transform healthcare
The fund, spearheaded by Charles Janssen, Ajay Mahipal, and Dr. Pinak Shrikhande, aims to invest between $7 million and $25 million per company across sectors including HealthTech, Life Sciences, MedTech, Healthcare Delivery, and Climate Health.
BUSINESS
Wockhardt looking at FY27 US launch for 'miracle' antibiotic Zaynich
The company is eyeing global market worth over $7 billion. Zaynich, a new antibiotic targeting the most severe of multi-drug resistant infections, has completed its global Phase III clinical study with impressive results
BUSINESS
SPARC rebound depends on trial outcomes of other assets, focused, lean R&D approach may help absorb setbacks
SPARC and its partner Sun Pharma said they will "evaluate the appropriate next steps", but the setback sent its shares tumbling nearly 18% on the BSE on Wednesday.
BUSINESS
Zydus Lifesciences in licensing deal with America's Agenus for cancer therapy
The agreement grants Zydus the rights to Agenus' next-generation immunotherapy platform, which is designed to enhance and sustain the immune system's fight against tumor cells.
BUSINESS
Glenmark’s myeloma drug delivers high response in phase-1 trial
At active dose levels (≥ 50 µg/kg), 26 of 33 evaluable patients (79%) achieved objective responses, including stringent or complete remissions in 30%, the company said.
BUSINESS
Trump drug pricing order to have limited credit impact on Indian pharma: CRISIL
The report says exports to the U.S. are dominated by generics, which already account for 90% of prescription volumes but just 13% of value, and are priced lower than in peer nations.
BUSINESS
Apollo Hospitals ready with Rs 8,000-crore expansion plan, to add 2,000 beds this fiscal
India's biggest healthcare player will likely have its new facilities in Bengaluru, Hyderabad, Gurugram, Kolkata and New Delhi up and running in the second half of FY26
BUSINESS
Delhi High Court restrains Dr.Reddy’s, OneSource from domestic sale of weight loss drug amid patent dispute
Justice Amit Bansal, presiding over the matter, recorded the defendants’ undertaking that they would not sell the impugned drug in India until the next hearing, scheduled for August 19, 2025. The court also took note of Novo Nordisk’s contention that even the export of an infringing product constitutes patent infringement under Indian law.
BUSINESS
Sun Pharma completes its acquisition of Checkpoint Therapeutics
Checkpoint Therapeutics is a Nasdaq-listed company focused on developing treatments for solid tumor cancers, including UNLOXCYT. The deal was valued at $355 million in cash and milestone payments.
